|
摘要：
|
|
摘要：目的 采用Meta分析评价肝癌、肝硬化及肝炎患者硒水平的差异。方法 通过计算
机检索PubMed、The Cochrane Library、Embas、Medline、万方数据库、中国生物医学
文献数据库、中国知网中有关肝癌、肝硬化及肝炎患者硒水平的文献并进行筛选及数
据提取。采用RevMan 5.3软件对不同肝病患者的硒水平进行Meta分析，异质性数据采
用随机效应模型分析，反之则采用固定效应模型分析。结果 本研究共纳入10篇文献，
共1497例患者，其中肝癌组324例，肝硬化组153例，肝炎组333例，对照组687例。肝
癌组、肝硬化组和肝炎组患者硒水平均显著低于健康组（WMD = －1.56，95%CI：
－2.08～－1.04，P ＜ 0.00001；WMD = －1.47，95%CI：－2.42～－0.52，P = 0.002；
WMD = －0.68，95%CI：－1.13～－0.23，P = 0.003），肝癌组患者硒水平显著低于肝
硬化组和肝炎组（WMD = －0.56，95%CI：－1.1～－0.1，P = 0.02；WMD = －1.0，
95%CI：－1.54～－0.46，P = 0.0003）；肝硬化组与肝炎组患者硒水平差异无统计学意
义（WMD = －0.38，95%CI：－0.87～0.11，P = 0.12）。结论 肝癌、肝硬化及肝炎患
者间硒水平存在显著差异，其中肝癌组患者硒水平下降最为明显。
|
|
Abstract: Objective To investigate the difference of selenium levels in patients with
liver cancer, liver cirrhosis and hepatitis by Meta-analysis. Methods Literature related to
selenium, hepatitis, liver cirrhosis and liver cancer in PubMed, The Cochrane Library, Embas,
Medline, Wanfang Data, China Biomedical Literature Database and CNKI were searched
through computer and perform screening and data extraction. Meta analysis of selenium
levels in patients with different liver diseases was conducted using RevMan 5.3 software.
Heterogeneity data was analyzed using a random effects model, and the fixed effects model
was used for heterogeneous data analysis. Results A total of 10 articles were included in this
study, including 1497 patients, of which 324 cases were with liver cancer, 153 cases were
with liver cirrhosis, 333 cases were with hepatitis and 687 cases were healthy controls. The
selenium levels of patients in liver cancer group, liver cirrhosis group and hepatitis group
were significantly lower than those in healthy group (WMD = －1.56, 95%CI：－2.08～
－1.04, P ＜ 0.001; WMD = －1.47, 95%CI: －2.42～－0.52, P = 0.002; WMD = －0.68,
95%CI: －1.13～－0.23, P = 0.003). The selenium level of patients in liver cancer group
was significantly lower than that of liver cirrhosis group and hepatitis group (WMD = －0.56,
95%CI: －1.1～－0.1, P = 0.02; WMD = －1.0, 95%CI: －1.54～－0.46, P = 0.0003). There
was no significant difference in selenium levels between patients in liver cirrhosis group and
hepatitis group (WMD = －0.38, 95%CI: －0.87～0.11, P = 0.12). Conclusion There is a
significant difference in selenium level among patients with liver cancer, liver cirrhosis and
hepatitis, with the most pronounced decline observed in liver cancer group.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|